Join Benzinga's Futures Fever for real-time trading insights powered by Apex Trader Funding. Featuring a discussion on ...
Cingulate Inc. (NASDAQ:CING) is one of the best NASDAQ growth stocks to buy and hold forever. On March 18, Cingulate reported its financial results for Q4 and the full year 2025, highlighting the ...
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with ...
Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...
Hosted on MSN
CING: Laying the foundation for 1H:27 launch
Cingulate, Inc. (NASDAQ: CING) reported 2025 results on March 18 th, 2026. The company generated no revenue and recorded operating expense of $20.0 million. The new drug application (NDA) submitted to ...
Cingulate Inc CING shares are trading lower after the company priced its $4-million public offering at around 58 cents per share and accompanying warrants. The offering includes 6.93 million shares ...
Cingulate Inc. Annual stock financials by MarketWatch. View the latest CING financial statements, income statements and financial ratios.
Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results